阿瑞匹坦治疗蕈样肉芽肿病瘙痒的随机交叉临床试验。
Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.
机构信息
Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
出版信息
JAMA Dermatol. 2018 Oct 1;154(10):1221-1222. doi: 10.1001/jamadermatol.2018.2510.
Abstract
This randomized clinical trial assesses whether treatment with the neurokinin 1 receptor antagonist aprepitant decreases pruritus vs placebo in patients with Sézary syndrome.
摘要
这项随机临床试验评估了神经激肽 1 受体拮抗剂阿瑞匹坦治疗与安慰剂相比是否能减少塞扎里综合征患者的瘙痒。
相似文献
1
Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.阿瑞匹坦治疗蕈样肉芽肿病瘙痒的随机交叉临床试验。
JAMA Dermatol. 2018 Oct 1;154(10):1221-1222. doi: 10.1001/jamadermatol.2018.2510.
2
Aprepitant as an antipruritic agent?阿瑞匹坦作为一种止痒剂？
N Engl J Med. 2009 Oct 1;361(14):1415-6. doi: 10.1056/NEJMc0906670.
3
[Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma].[阿瑞匹坦在皮肤T细胞淋巴瘤患者瘙痒管理中的作用]
Farm Hosp. 2014 Apr 1;38(2):145-7.
4
Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.用阿瑞匹坦治疗早期色素减退型蕈样肉芽肿的瘙痒症。
Dermatol Ther. 2014 May-Jun;27(3):178-82. doi: 10.1111/dth.12113. Epub 2013 Dec 2.
5
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).阿瑞匹坦治疗抗组胺药物难治性慢性结节性痒疹的多中心、随机、双盲、安慰剂对照、交叉、Ⅱ期临床试验（APREPRU）。
Acta Derm Venereol. 2019 Apr 1;99(4):379-385. doi: 10.2340/00015555-3120.
6
Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study.阿瑞匹坦治疗大疱性表皮松解症和特应性皮炎患者难治性瘙痒的疗效：一项回顾性研究。
Pediatr Dermatol. 2024 Sep-Oct;41(5):819-821. doi: 10.1111/pde.15704. Epub 2024 Jul 25.
7
Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.阿瑞匹坦：其对难治性瘙痒患者有效性的证据仍在不断涌现。
J Am Acad Dermatol. 2012 Jan;66(1):e14-5. doi: 10.1016/j.jaad.2011.01.016.
8
Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.阿瑞匹坦的止痒作用与抗肿瘤作用：剂量问题
Acta Derm Venereol. 2019 May 1;99(6):620-621. doi: 10.2340/00015555-3148.
9
Aprepitant for the Treatment of Chronic Refractory Pruritus.阿瑞匹坦治疗慢性难治性瘙痒症。
Biomed Res Int. 2017;2017:4790810. doi: 10.1155/2017/4790810. Epub 2017 Sep 19.
10
Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report.伴霍奇金淋巴瘤的副肿瘤性瘙痒：一例报告
J Med Case Rep. 2014 Sep 8;8:300. doi: 10.1186/1752-1947-8-300.
引用本文的文献
1
What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.皮肤 T 细胞淋巴瘤相关瘙痒的新进展。
Am J Clin Dermatol. 2024 Jan;25(1):67-77. doi: 10.1007/s40257-023-00823-2. Epub 2023 Nov 16.
2
An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.原发性皮肤 T 细胞淋巴瘤瘙痒机制及其潜在治疗方法的最新进展。
Clin Exp Med. 2023 Dec;23(8):4177-4197. doi: 10.1007/s10238-023-01141-x. Epub 2023 Aug 9.
3
Neurokinin 1 Receptor Antagonists for Pruritus.神经激肽 1 受体拮抗剂治疗瘙痒。
Drugs. 2021 Apr;81(6):621-634. doi: 10.1007/s40265-021-01478-1. Epub 2021 Mar 6.
4
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?神经激肽-1受体拮抗剂阿瑞匹坦：对抗癌症的智能子弹？
Cancers (Basel). 2020 Sep 20;12(9):2682. doi: 10.3390/cancers12092682.
5
NK-1 Receptor Antagonists and Pruritus: Review of Current Literature.NK-1受体拮抗剂与瘙痒：当前文献综述
Dermatol Ther (Heidelb). 2019 Sep;9(3):391-405. doi: 10.1007/s13555-019-0305-2. Epub 2019 Jun 12.
6
The Itch-Scratch Cycle: A Neuroimmune Perspective.瘙痒-搔抓循环：神经免疫观点。
Trends Immunol. 2018 Dec;39(12):980-991. doi: 10.1016/j.it.2018.10.001. Epub 2018 Nov 21.
本文引用的文献
1
Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.阿瑞匹坦治疗难治性皮肤T细胞淋巴瘤相关瘙痒：4例病例及文献综述
BMC Cancer. 2017 Mar 16;17(1):200. doi: 10.1186/s12885-017-3194-8.
2
Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.皮肤 T 细胞淋巴瘤：以靶向药物为重点的综述。
Am J Clin Dermatol. 2016 Jun;17(3):225-37. doi: 10.1007/s40257-016-0177-5.
3
Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.用阿瑞匹坦治疗早期色素减退型蕈样肉芽肿的瘙痒症。
Dermatol Ther. 2014 May-Jun;27(3):178-82. doi: 10.1111/dth.12113. Epub 2013 Dec 2.
4
Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.阿瑞匹坦治疗皮肤T细胞淋巴瘤继发的难治性瘙痒
Actas Dermosifiliogr. 2014 Sep;105(7):716-8. doi: 10.1016/j.ad.2013.07.007. Epub 2013 Oct 16.
5
Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.阿瑞匹坦：一种新型神经激肽-1受体/ P物质拮抗剂，用于皮肤T细胞淋巴瘤的止痒治疗。
J Am Acad Dermatol. 2012 Nov;67(5):e198-9. doi: 10.1016/j.jaad.2012.02.008.
6
Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.口服阿瑞匹坦治疗红皮病型皮肤T细胞淋巴瘤难治性瘙痒
Br J Dermatol. 2011 Mar;164(3):665-7. doi: 10.1111/j.1365-2133.2010.10108.x. Epub 2011 Jan 28.
Zotero 插件